08 April 2026 : Clinical Research
Efficacy and Safety of Liposomal Bupivacaine in Direct Anterior Approach Total Hip Arthroplasty: A Retrospective Cohort Study
Ye Chen
ABCDEF 1, Chunxiao Zhang AD 2, Lanyong Chen B 1, Yong He B 1, Linling Zhang B 1, Songfeng Hu AG 1,2*
DOI: 10.12659/MSM.951717
Med Sci Monit 2026; 32:e951717
Table 1 Comparison of general baseline information between the liposomal bupivacaine (LB) and ropivacaine groups.
| General baseline information | LB group (n=61) | Ropivacaine group (n=68) | SMD | P value |
|---|---|---|---|---|
| Sex [case (%)] | ||||
| Male | 22 (36.07) | 23 (33.82) | 0.05 | 0.790 |
| Female | 39 (63.93) | 45 (66.18) | ||
| Age (years) | 71.52±9.91 | 71.81±10.37 | −0.03 | 0.699 |
| BMI (kg/m) | 25.84±2.73 | 25.22±3.27 | 0.20 | 0.382 |
| Surgical side [case (%)] | ||||
| Left | 23 (37.70) | 33 (48.53) | 0.22 | 0.216 |
| Right | 38 (62.30) | 35 (51.47) | ||
| Preoperative ASA Classification [case (%)] | ||||
| II | 48 (78.69) | 55 (80.88) | 0.05 | 0.757 |
| III | 13 (21.31) | 13 (19.12) | ||
| Disease type [case (%)] | ||||
| Femoral head necrosis | 13 (21.31) | 13 (19.12) | 0.05 | 0.757 |
| Femoral neck fracture | 48 (78.69) | 55 (80.88) | ||
| Operation time (min) | 84.02±22.82 | 82.43±25.66 | 0.07 | 0.309 |
| Incision length (cm) | 12.51±3.33 | 12.63±3.52 | −0.04 | 0.988 |
| Data are presented as mean±SD or number of patients (%). An absolute standardized mean difference (SMD) value | ||||